


# BIOGEN



PHARMACHEM INDUSTRIES LIMITED

CIN NO: L51100GJ1995PLC026702

(Formerly Known as SUN TECHNO OVERSEAS LIMITED)

Date: 12.02.2022

To,  
Department of Corporate Services  
BSE Limited,  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai - 400 001

Dear Sir / Madam,

**Sub: Unaudited Financial Result for quarter ending 31<sup>st</sup> December 2021 pursuant to Regulation 33 of the SEBI (LODR) Regulations, 2015**

In compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached herewith unaudited financial result for quarter ended 31<sup>st</sup> December 2021.

Kindly take the same on your record and oblige.

Thanking You.

**FOR, BIOGEN PHARMACHEM INDUSTRIES LIMITED**



**DIRECTOR/AUTHORISED SIGNATORY**

**Registered Office Address: Shop No. 8, First Floor, Makers - 1 Building, Jawahar Road, Rajkot-360001**  
**E mail [biogenpharmachem@gmail.com](mailto:biogenpharmachem@gmail.com)**

# BIOGEN PHARMACHEM INDUSTRIES LIMITED

CIN:- L65910GJ1995PLC026702

Regd. Office: Shop No. 8, First Floor, Makers - 1 Building, Jawahar Road, Rajkot - 360001

Email:- suntechnooverseas@gmail.com

Statement of Unaudited Financial Results for the Quarter Ended December 31, 2021

(Rs. In lacs)							
Sl No.	Particulars	Quarter Ended 31 Dec'2021	Quarter Ended 30 Sept'2021	Quarter Ended 31 Dec'2020	Nine Monts Ended 31 Dec'2021	Nine Monts Ended 31 Dec'2020	Year Ended 31 Mar 2021
	(Refer Notes Below)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
<b>1</b>	<b>Income</b>						
(a)	Revenue from Operations	-	122.27	-	247.42	-	162.26
(b)	Other Income	2.87	(16.43)	(210.57)	(13.56)	(210.57)	(160.81)
	<b>Total Income from Operations (Net)</b>	<b>2.87</b>	<b>105.84</b>	<b>(210.57)</b>	<b>233.86</b>	<b>(210.57)</b>	<b>1.45</b>
<b>2</b>	<b>Expenses</b>						
(a)	Cost of material consumed	-	103.25	-	201.49	-	148.06
(b)	Purchase of stock in trade	-	-	-	-	-	-
(c)	Changes in inventories of finished goods, work-in-progress, and stock-in-trade	-	-	-	-	-	-
(d)	Employee benefit expense	1.32	1.36	0.90	4.10	0.90	1.39
(e)	Finance Costs	-	-	-	-	-	-
(f)	Depreciation and Amortization Expense	-	-	-	-	-	-
(g)	Other expenses	0.47	0.16	10.78	6.03	11.02	12.32
	<b>Total Expenses</b>	<b>1.79</b>	<b>104.77</b>	<b>11.68</b>	<b>211.62</b>	<b>11.92</b>	<b>161.77</b>
<b>3</b>	<b>Profit / (Loss) from operations before exceptional items and Tax (1-2)</b>	<b>1.08</b>	<b>1.07</b>	<b>(222.25)</b>	<b>22.24</b>	<b>(222.49)</b>	<b>(160.32)</b>
<b>4</b>	<b>Exceptional Items</b>						
<b>5</b>	<b>Profit / (Loss) before Tax (3 ± 4)</b>	<b>1.08</b>	<b>1.07</b>	<b>(222.25)</b>	<b>22.24</b>	<b>(222.49)</b>	<b>(160.32)</b>
<b>6</b>	<b>Tax Expense</b>	-	-	-	-	-	-
<b>7</b>	<b>Profit / (Loss) after tax (5 - 6)</b>	<b>1.08</b>	<b>1.07</b>	<b>(222.25)</b>	<b>22.24</b>	<b>(222.49)</b>	<b>(160.32)</b>
<b>8</b>	<b>Other comprehensive income (Net of Tax)</b>						
A.	(i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified profit or	-	-	-	-	-	-
B.	(i) Items that will be reclassified to Profit or Loss	-	-	-	-	-	-
<b>9</b>	<b>Total comprehensive income (7 ± 8)</b>	<b>1.08</b>	<b>1.07</b>	<b>(222.25)</b>	<b>22.24</b>	<b>(222.49)</b>	<b>(160.32)</b>
<b>10</b>	<b>Paid-up equity share capital (Face Value of Rs. 1/- each)</b>	<b>6,526.03</b>	<b>6,526.03</b>	<b>6,526.03</b>	<b>6,526.03</b>	<b>6,526.03</b>	<b>6,526.03</b>
<b>11</b>	<b>Other Equity</b>						(1,111.75)
<b>12</b>	<b>Earnings Per Share (before extraordinary items) (of Rs. 1/- each) (not annualised):</b>						
(a)	Basic	0.00	0.00	(0.03)	0.00	(0.03)	(0.02)
(b)	Diluted	0.00	0.00	(0.03)	0.00	(0.03)	(0.02)

**Notes:**

- The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on February 12, 2022. The Statutory Auditors have carried out a limited review of the above financial result.
- Company has only one segment and hence no separate segment result has been given.
- The figure of previous period/year have been re-grouped / re-arranged and /or recast wherever found necessary.
- This statement is as per Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

Place : Rajkot

Date : 12th February, 2022

By order of the Board

Director





# RISHI SEKHRI AND ASSOCIATES CHARTERED ACCOUNTANTS

GROUND FLOOR, BANDRA ARCADE BUILDING, OPP. RAILWAY STATION, BANDRA (WEST), MUMBAI - 400 050.  
Tel.: 9820501848, 26419136, Email : rishisekhri@gmail.com

## Limited Review Report

To  
The Board of Directors of  
**Biogen Pharmachem Industries Limited**  
Rajkot

We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **Biogen Pharmachem Industries Limited** ("the Company"), for the Quarter ended on December 31, 2021 and year to date result for the period from 01 April, 2021 to 31 December, 2021 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

FOR, RISHI SEKHRI AND ASSOCIATES,  
Chartered Accountants  
FRN: 128216W

  
CA RISHI SEKHRI  
PARTNER  
MEMBERSHIP NO. 126656  
PLACE: MUMBAI  
DATE: 12.02.2022  
UDIN: 22126656ABOTQR9991

